MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often associated with oral nintedanib. Speaking during a conference panel on IPF therapies, […]
23 Oct 11:03 · The Markets Daily